Preview

Онкогематология

Расширенный поиск

Пути улучшения результатов лечения злокачественных опухолей у подростков и молодых взрослых

https://doi.org/10.17650/1818-8346-2011-6-1-20-29

Полный текст:

Аннотация

В настоящей статье представлен обзор клинических и биологических особенностей наиболее часто встречающихся злокачественных опухолей у подростков и молодых взрослых. На основе собственного опыта обобщены сведения по наиболее эффективным педиатрическим и общеонкологическим подходам к лечению описанных патологий.

Об авторах

А. Г Румянцев
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Росздрава
Россия


В. В. Птушкин
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Росздрава
Россия


С. В. Семочкин
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии Росздрава
Россия


Список литературы

1. Bleyer A., O’Leary M., Barr R., Ries L.A.G. Cancer Epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence & survival 1975–2000. Pub. NCI 2006.

2. Семочкин С.В. Оптимизация технологий лечения лимфопролиферативных заболеваний у подростков и лиц молодого возраста. Автореф. дис. … д-ра мед. наук. М., 2007.

3. Thomas D.M., Seymour J.F., O'Brien T. et al. Adolescent and young adult cancer: a revolution in evolution? Intern Med J 2006;36(5):302–7.

4. Демографический ежегодник России. 2009: Стат. сб. / Росстат. M., 2009. 557 c.

5. Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 2005;35(5):182–217.

6. Downs-Canner S., Shaw P.H. A comparison of clinical trial enrollment between adolescent and young adult (AYA) oncology patients treated at affiliated adult and pediatric oncology centers. J Pediatr Hematol Oncol 2009;31(12):927–9.

7. Relling M.V., Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001;1:99–108.

8. Pieters R., den Boer M.L., Durian M. et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998;12:1344–6.

9. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009;20(3): прил. 1.

10. Agaram N.P., Laquaglia M.P., Ustun B. et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008;14(10):3204–15.

11. Platell C., Zeps N., Joseph D. et al. Tumour banking as part of routine clinical practice. ANZ J Surg. 2010;80(4):203–4.

12. Физиология роста и развития детей и подростков (теоретические и практические вопросы). Под ред. А.А. Баранова, Л.А. Щеплягиной. М.: Гэотар-Медиа, 2006, том 1. 416 с.

13. Pacifici G.M. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 2009;65(4):419–27.

14. Ginsberg G., Hattis D., Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004;198(2):164–83.

15. McLeod H.L., Relling M.V., Crom W.R. et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:23–9.

16. Groninger E., Proost J.H., de Graaf S.S. Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol 2004;52(3):173–97.

17. Румянцев А.Г., Варфоломеева С.Р., Осипов С.Г. и др. Основные инструменты доказательной медицины в детской гематологии/онкологии. Вопр гематол онкол и иммунопатол педиатр 2009;8(1):5–17.

18. Sala A., Mattano L.A. Jr., Barr R.D. Osteonecrosis in children and adolescents with cancer — an adverse effect of systemic therapy. Eur J Cancer 2007;43(4):683–9.

19. McCarville M.B., Adelman C.S., Li C. et al. Typhlitis in childhood cancer. Cancer 2005;104:380–7.

20. Prucker C., Attarbaschi A., Peters C. et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a populationbased analysis of the Austrian Berlin-Frankfurt-Münster study group. Leukemia 2009;23(7):1264–9.

21. Balducci L. Management of chemotherapy-induced neutropenia in the older cancer patient. Oncology (Williston Park) 2006;20(14, Suppl 9):26–31.

22. Huguet F., Leguay T., Raffoux E. et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27(6):911–8.

23. Pui C.H. Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 2009;27(31):5121–3.

24. Möricke A., Zimmermann M., Reiter A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24(2):265–84.

25. Thomas X., Boiron J.M., Huguet F. et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075–86.

26. Göekbuget N., Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009;46(1):64–75.

27. Gaynon P.S., Angiolillo A.L., Carroll W.L. et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Leukemia 2010;24(2):285–97.

28. Nachman J., Sather H.N., Buckley J.D. et al. Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71:3377–85.

29. Vilmer E., Suciu S., Ferster A. et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia 2000;14:2257–66.

30. Gleissner B., Gukbuget N., Bartram C.R. et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536–43.

31. Mancini M., Scappaticci D., Cimino G. et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005;105:3434–41.

32. Семочкин С.В., Лория С.С., Куликова С.С. и др. Современные подходы к терапии острого лимфобластного лейкоза у подростков и лиц молодого возраста. Вопр гематол онкол и иммунопатол педиатр 2009;8(1):26–32.

33. Stock W., La M., Sanford B. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112(5):1646–54.

34. Boissel N., Auclerc M.F., Lheritier V. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774–80.

35. De Bont J.M., Holt B., Dekker A.W. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004;18:2032–5.

36. Ribera J.M., Oriol A., Sanz M.A. et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol 2008;26(11):1843–9.

37. Usvasalo A., Räty R., Knuutila S. et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland.Haematologica 2008;93(8):1161–8.

38. Goldstone A.H., Richards S.M., Lazarus H.M. et al. In adults with standardrisk acute lymphoblastic leukemia, the greatest enefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827–33.

39. Ramanujachar R., Richards S., Hann I., Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer 2006;47(6):748–56.

40. Harrison C.J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009;144(2):147–56.

41. Shipp M.A., Harrington D.P., Anderson J.R. et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987–94.

42. Самочатова Е.В. Неходжкинские лимфомы у детей: от патогенетической классификации к успешной терапии. Вопр гематол онкол и иммунопатол педиатр 2007;6(4):5–12.

43. Reiter A., Schrappe M., Parwaresch R. et al. NHL of childhood and adolescence: Results of a Treatment stratified for biologic subtypes and stage. A report of the BFM Group. J Clin Oncol 1995;13(2):359–72.

44. Klapper W., Szczepanowski M., Burkhardt B. et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 2008;112(4):1374–81.

45. Lenz G., Wright G.W., Emre N.C. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105(36):13520–5.

46. Hans C.P., Weisenburger D.D., Greiner T.C. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Blood 2004;103(1):275–82.

47. Семочкин С.В., Бобкова М.М., Лория С.С. и др. Опыт терапии подростков и взрослых больных с неходжкинскими лимфомами по педиатрическому протоколу NHL-BFM-90m. Вопр гематол онкол и иммунопатол педиатр 2007;6(1):18–25.

48. Бобкова М.М., Семочкин С.В., Иванова В.Л. и др. Эффективность применения интенсивной полихимиотерапии в лечении молодых больных с диффузной В-крупноклеточной лимфомой из клеток герминального центра. Онкогематология 2009;4:4–11.

49. Jain S., Xu R., Prieto V.G., Lee P. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol 2010 Apr 23;3(4):416–28.

50. Hattinger C.M., Pötschger U., Tarkkanen M. et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002 Jun 5;86(11):1763–9.

51. Evan E.E., Zeltzer L.K. Psychosocial dimensions of cancer in adolescents and young adults. Cancer 2006;107:1663–71.

52. Clinton-McHarg T., Carey M., Sanson- Fisher R. et al. Measuring the psychosocial health of adolescent and young adult (AYA) cancer survivors: a critical review. Health Qual Life Outcomes 2010;8:25.

53. Freyer D.R., Brugieres L. Adolescent and young adult oncology: transition of care. Pediatr Blood Cancer 2008;50 (5 Suppl):1116–9.

54. Subbiah V. Adolescent oncology: who cares?-the new KID on the block. Support Care Cancer 2010;18(6):771–3.


Для цитирования:


Румянцев А.Г., Птушкин В.В., Семочкин С.В. Пути улучшения результатов лечения злокачественных опухолей у подростков и молодых взрослых. Онкогематология. 2011;6(1):20-29. https://doi.org/10.17650/1818-8346-2011-6-1-20-29

For citation:


Rumyantsev A.G., Ptushkin V.V., Semochkin S.V. Approaches to improvement of treatment results of malignant tumors in adolescents and young adults. Oncohematology. 2011;6(1):20-29. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-1-20-29

Просмотров: 426


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)